15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Gilead Sciences Inc, 14 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $120.00 to $180.00, a moderate spread. The average target of $159.57 sits 19% above the current $134.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.20 next quarter toward $9.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Strong Buy
Strong Buy00%
Buy1488%
Hold213%
Sell00%
Strong Sell00%
Based on 16 analysts giving stock ratings to Gilead Sciences Inc.
As of Jul, 14 of 16 firms rate GILD a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GILD EPS & revenue forecast
EPS · NEXT QUARTER
$2.20
Range $1.41 – $2.44 · 19 analysts · -11% YoY
Next period, 19 analysts expect Gilead Sciences Inc to earn $2.20 a share (range $1.41 – $2.44), versus $2.47 a year earlier. Full-year consensus is $-0.77, growing to $9.63 the year after.
REVENUE · NEXT QUARTER
$7.8B
Range $7.5B – $8.1B · 19 analysts · +0% YoY
Revenue is expected to reach $7.8B (range $7.5B – $8.1B), +0.3% year-over-year. Full-year consensus is $30.4B, rising to $32.3B next year.
Top analysts covering Gilead Sciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GILD.
#1
Joseph Stringer
Needham · Rank #168
Buy
$170.00+26.5% to target
Overall win rate
36%
+ Follow
#2
Matthew Harrison
Morgan Stanley · Rank #243
Buy
$166.00+23.5% to target
Overall win rate
44%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$162.00+20.5% to target
Overall win rate
41%
+ Follow
#4
Brian Abrahams
RBC Capital · Rank #311
Hold
$120.00-10.7% to target
Overall win rate
25%
+ Follow
#5
GR
Gregory Renza
Truist Securities
Buy
$156.00+16.1% to target
Coverage
—
+ Follow
GILD stock forecast FAQ
What is GILD's average 12-month price target?+
The 14 analysts with a live target average $159.57 for Gilead Sciences Inc over the next 12 months, ranging from a $180.00 high to a $120.00 low.
Is GILD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 16 analyst ratings, 14 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GILD?+
The Street-high target is $180.00 (Jefferies), and the Street-low is $120.00 (RBC Capital). The average of all 14 active targets is $159.57.
How many Wall Street analysts cover GILD?+
16 analysts have an active rating on Gilead Sciences Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering GILD?+
Among analysts who currently cover GILD, Joseph Stringer of Needham has the strongest overall Quantellect track record (Rank #168). Their current call is Buy with a $170.00 target.
What is Gilead Sciences Inc's projected EPS for next quarter?+
The consensus estimate is $2.20 per share (range $1.41 – $2.44) across 19 analysts. Full-year EPS is projected at $-0.77, rising to $9.63 the following year.
How much revenue is Gilead Sciences Inc expected to report next quarter?+
Consensus revenue is $7.8B (range $7.5B – $8.1B). Full-year revenue is projected at $30.4B, growing to $32.3B next year.
Have analysts been upgrading or downgrading GILD lately?+
As of Jul, 14 of 16 firms rate GILD a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GILD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
